CY1123449T1 - Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων - Google Patents

Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων

Info

Publication number
CY1123449T1
CY1123449T1 CY20201100971T CY201100971T CY1123449T1 CY 1123449 T1 CY1123449 T1 CY 1123449T1 CY 20201100971 T CY20201100971 T CY 20201100971T CY 201100971 T CY201100971 T CY 201100971T CY 1123449 T1 CY1123449 T1 CY 1123449T1
Authority
CY
Cyprus
Prior art keywords
preparing
mini tablets
present
melatonin mini
melatonin
Prior art date
Application number
CY20201100971T
Other languages
English (en)
Inventor
Moshe Laudon
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57482481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123449(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals Ltd filed Critical Neurim Pharmaceuticals Ltd
Publication of CY1123449T1 publication Critical patent/CY1123449T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση απευθύνεται γενικά σε ένα φιλικό προς τον ασθενή σύστημα αποδέσμευσης φαρμάκου για στοχευμένους πληθυσμούς, όπως παιδιατρικούς και γηριατρικούς ασθενείς. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με μια φαρμακευτική σύνθεση στη μορφή μίνι δισκίων. Ακόμη πιο συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με μια φαρμακευτική σύνθεση η οποία περιλαμβάνει μια θεραπευτικά αποτελεσματική ποσότητα μελατονίνης στη μορφή μίνι δισκίων.
CY20201100971T 2016-10-31 2020-10-14 Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων CY1123449T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662415014P 2016-10-31 2016-10-31
PCT/IB2016/057190 WO2018078429A1 (en) 2016-10-31 2016-11-29 Melatonin mini-tablets and method of manufacturing the same

Publications (1)

Publication Number Publication Date
CY1123449T1 true CY1123449T1 (el) 2022-03-24

Family

ID=57482481

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100971T CY1123449T1 (el) 2016-10-31 2020-10-14 Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων

Country Status (23)

Country Link
US (2) US10722494B2 (el)
EP (2) EP3337462B1 (el)
JP (1) JP6830156B2 (el)
KR (1) KR102167190B1 (el)
CN (1) CN109922795B (el)
AU (5) AU2016426598C1 (el)
CA (1) CA3040027C (el)
CY (1) CY1123449T1 (el)
DK (1) DK3337462T3 (el)
ES (1) ES2828034T3 (el)
HR (1) HRP20201722T1 (el)
HU (1) HUE051362T2 (el)
IL (1) IL262537B (el)
LT (1) LT3337462T (el)
MX (1) MX2019004736A (el)
NZ (1) NZ747702A (el)
PL (1) PL3337462T3 (el)
PT (1) PT3337462T (el)
RS (1) RS61024B1 (el)
SG (1) SG11201903829PA (el)
SI (1) SI3337462T1 (el)
TW (1) TWI787164B (el)
WO (1) WO2018078429A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof
KR20230017814A (ko) * 2020-10-26 2023-02-06 일동제약(주) 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제
WO2024079125A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. Sustained release melatonin compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
ES2134789T3 (es) 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
IL105240A (en) 1992-04-07 1999-04-11 Neurim Pharma 1991 The use of melatonin in the preparation of a drug for the treatment of benign prostatic hyperplasia
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
AU7550994A (en) * 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
EP1117384A1 (en) * 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
EE200200379A (et) 2000-01-05 2003-10-15 Neurim Pharmaceuticals (1991) Ltd. Meetod ja preparaat antihüpertensiivsete ainete suhtes resistentsuse ja sellega seotud haigusseisundite raviks
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
KR20030016215A (ko) * 2002-07-05 2003-02-26 뉴림 파머슈티칼스 (1991) 리미티드 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
AU2004308962A1 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
CN101754753A (zh) 2007-05-24 2010-06-23 纽约市哥伦比亚大学托管会 褪黑素的持久释放配方
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
ES2677247T3 (es) 2014-05-28 2018-07-31 Valpharma S.P.A. Formulación para administración oral que comprende melatonina en forma estable y método de producción de la misma

Also Published As

Publication number Publication date
SI3337462T1 (sl) 2021-01-29
TW201817418A (zh) 2018-05-16
DK3337462T3 (da) 2020-10-12
RS61024B1 (sr) 2020-12-31
AU2016426598A1 (en) 2018-05-17
TWI787164B (zh) 2022-12-21
PT3337462T (pt) 2020-10-30
KR20190014512A (ko) 2019-02-12
IL262537B (en) 2021-03-25
JP2019533672A (ja) 2019-11-21
ES2828034T3 (es) 2021-05-25
CN109922795A (zh) 2019-06-21
EP3337462B1 (en) 2020-09-30
US10722494B2 (en) 2020-07-28
AU2023202003A1 (en) 2023-05-04
SG11201903829PA (en) 2019-05-30
HRP20201722T1 (hr) 2021-03-05
AU2021200268A1 (en) 2021-03-18
AU2019200479B2 (en) 2020-10-22
CA3040027C (en) 2023-08-15
AU2019200479A1 (en) 2019-02-14
AU2016426598C1 (en) 2024-02-08
US20200306227A1 (en) 2020-10-01
IL262537A (en) 2018-12-31
MX2019004736A (es) 2019-06-17
NZ747702A (en) 2022-08-26
US20190060277A1 (en) 2019-02-28
CN109922795B (zh) 2021-10-08
LT3337462T (lt) 2021-01-11
AU2019101470B4 (en) 2020-06-25
AU2016426598B2 (en) 2018-11-01
HUE051362T2 (hu) 2021-03-01
JP6830156B2 (ja) 2021-02-17
US10869857B2 (en) 2020-12-22
WO2018078429A1 (en) 2018-05-03
EP3777842A1 (en) 2021-02-17
KR102167190B1 (ko) 2020-10-19
EP3337462A1 (en) 2018-06-27
PL3337462T3 (pl) 2021-01-25
AU2019101470A4 (en) 2020-01-16
CA3040027A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
CY1123449T1 (el) Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων
BR112018010650A8 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112017012381A2 (pt) imunoterapia para doença angiogênica
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
IN2014MU00303A (el)
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
BR112018009946A8 (pt) pró-fármacos de ácido nucleico
PE20180928A1 (es) Sales y profarmacos de 1-metil-d-triptofano
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IN2014MU00916A (el)
MD4763B1 (ro) Compoziţie farmaceutică